Sometimes, diabetes science confuses me.
Let’s take the news of an emerging class of diabetes drugs (type 2-focused) that apparently do something we’ve always thought was bad… but it’s actually not.
Sodium-glucose transporter (SGLT-2) inhibitors increase insulin production and effectiveness and stop the liver from producing too much glucose. Basically, they work by spilling glucose over into the urine which leads to less sugar in your bloodstream. The effect: lower BGs and A1Cs.
Sure, it…
Read more »
The biggest thing in diabetes headlines of late is Bydureon, the first and only once-a-week drug to help type 2 diabetics keep their sugars in check, which is newly approved by the FDA. Amylin’s stock price is up, and the pharma blogosphere is all abuzz. But if you’re like us, you may be wondering what the really big deal is. New type 2 drugs come out all the time, don’t they?
Well, for one thing,…
Read more »
By
WilD on
November 26, 2011
Welcome back to our Saturday diabetes advice column, Ask D’Mine, hosted by veteran type 1, diabetes author and community educator Wil Dubois — where myths get busted and unseemly topics sometimes see the light of day. Hey, where else ya gonna turn?
{Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com}
First things first this week:
Exercising over 250 mg/dL CORRECTION:
Last week we talked about how it’s generally considered unsafe to start…
Read more »
